SHR-A1811 + adebrelimab + capecitabine + fluorouracil

This combination consists of four anticancer drugs: **SHR-A1811**, an antibody-drug conjugate targeting HER2; **adebrelimab**, an anti-PD-L1 monoclonal antibody; **capecitabine**, an orally administered prodrug of 5-fluorouracil; and **fluorouracil (5-FU)**, a pyrimidine analog antimetabolite. - **SHR-A1811** selectively delivers a cytotoxic payload to HER2-expressing tumor cells, causing targeted cancer cell death by disrupting microtubule function[1][4]. - **Adebrelimab** enhances immune response against tumors by blocking the interaction of PD-L1 with PD-1, enabling T-cell mediated antitumor activity. - **Capecitabine** is metabolized to 5-FU, which inhibits thymidylate synthase, effectively blocking DNA synthesis in rapidly proliferating cells[2][3][5]. - **Fluorouracil (5-FU)** interferes with DNA and RNA synthesis by acting as a pyrimidine analog, further inhibiting tumor cell proliferation. This combination is under investigation for advanced solid tumors, particularly HER2-expressing cancers and may be explored for synergistic effects in combination immunochemotherapy regimens.

Other names

5-FU5-fluorouracil